Artiva Biotherapeutics (ARTV) Q1 2026 earnings summary

Executive summary

• AlloNK advanced in clinical trials for refractory RA, Sjögren's disease, and systemic sclerosis, with over 70 autoimmune patients treated and more than 40 clinical sites activated globally as of April 30, 2026.

• Initial AlloNK clinical data showed a 71% ACR50 response in refractory RA patients with at least six months of follow-up, with no relapses, no cytokine release syndrome, and no serious adverse events related to AlloNK.

• AlloNK demonstrated deep B-cell depletion and a favorable tolerability profile, supporting outpatient use in community rheumatology settings.

• Clinical responses in Sjögren's disease and systemic sclerosis were consistent with RA data, supporting AlloNK's potential across B-cell-driven autoimmune diseases.

• FDA alignment achieved on a single registrational Phase 3 trial design for AlloNK in refractory RA, targeting approximately 150 patients, with trial initiation expected in the second half of 2026.

Financial highlights

• Net loss for the quarter ended March 31, 2026, was $23.5 million, compared to $20.3 million for the same period in 2025.

• Research and development expenses increased to $19.3 million from $17.1 million year-over-year, primarily due to higher AlloNK clinical trial costs.

• Cash, cash equivalents, and investments totaled $86.8 million as of March 31, 2026, expected to fund operations into Q2 2027.

• General and administrative expenses remained flat at $5.1 million for Q1 2026 and Q1 2025.

• Accumulated deficit reached $354.1 million as of March 31, 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations into the second quarter of 2027.

• Additional funding will be required to complete clinical development and commercialization activities.

• Phase 3 trial for AlloNK in refractory RA planned to start in the second half of 2026, enrolling approximately 150 patients, with primary efficacy data expected in the second half of 2028 and potential BLA submission in 2029.

• Multiple presentations of AlloNK clinical data scheduled for EULAR 2026, including late-breaking and oral abstracts.